| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/02/2002 | EP1200560A1 Melanin-concentrating hormone receptor |
| 05/02/2002 | EP1200470A2 Globular assembly of amyloid beta protein and uses thereof |
| 05/02/2002 | EP1200458A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 05/02/2002 | EP1200457A2 Cysteine protease inhibitors |
| 05/02/2002 | EP1200447A1 Oxazinocarbazoles for the treatment of cns diseases |
| 05/02/2002 | EP1200446A1 OXATHIEPINO 6,5- i b /i ]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 05/02/2002 | EP1200445A1 Thienopyranecarboxamide derivatives |
| 05/02/2002 | EP1200442A1 2,3-benzodiazepine derivatives |
| 05/02/2002 | EP1200440A1 Quinuclidine derivatives for treatment of neurological disorders |
| 05/02/2002 | EP1200433A1 C-6 RING-SUBSTITUTED PYRIDO 1,2- i a /i ]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS |
| 05/02/2002 | EP1200432A1 Amido spiropiperidines promote the release of growth hormone |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200419A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 05/02/2002 | EP1200415A1 Diamino-1,2,4-triazole-carboxylic acid derivatives as gsk-3 inhibitors |
| 05/02/2002 | EP1200410A1 Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance |
| 05/02/2002 | EP1200409A2 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 05/02/2002 | EP1200402A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 05/02/2002 | EP1200400A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 05/02/2002 | EP1200398A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 05/02/2002 | EP1200151A1 Drug delivery device for insertion into the vagina, rectum or nasal cavity |
| 05/02/2002 | EP1200133A1 Manipulation of tissue or organ type using the notch pathway |
| 05/02/2002 | EP1200127A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 05/02/2002 | EP1200124A1 Immunoglobulin fusion proteins |
| 05/02/2002 | EP1200114A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 05/02/2002 | EP1200106A1 Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement |
| 05/02/2002 | EP1200103A1 Xenon as nmda antagonist |
| 05/02/2002 | EP1200089A1 Pyridomorphinans and use thereof |
| 05/02/2002 | EP1200086A2 Methods for treating or preventing pain and anxiety |
| 05/02/2002 | EP1200085A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 05/02/2002 | EP1200081A1 Treatment of neurotic disorders |
| 05/02/2002 | EP1200080A1 Assay for d-serine transport antagonist and use for treating psychosis |
| 05/02/2002 | EP1200078A1 Compositions and methods for promoting nerve regeneration |
| 05/02/2002 | EP1200073A2 SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 05/02/2002 | EP1200072A2 Method of treating psychotic disorders |
| 05/02/2002 | EP1200064A1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
| 05/02/2002 | EP0885004B1 Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
| 05/02/2002 | EP0841907B1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 05/02/2002 | EP0804199B1 Use of penciclovir for the treatment of post herpetic neuralgia |
| 05/02/2002 | EP0772442B1 Use of immunosuppressive agents for the treatment of schizophrenia |
| 05/02/2002 | EP0746567B1 Novel opioid peptides for the treatment of pain and use thereof |
| 05/02/2002 | EP0607164B1 Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists |
| 05/02/2002 | DE10140029A1 Vefahren zur Herstellung von Citalopram Vefahren for the preparation of citalopram |
| 05/02/2002 | DE10053397A1 Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases |
| 05/02/2002 | DE10052658A1 Neue Pyranosidderivate New Pyranosidderivate |
| 05/02/2002 | DE10052333A1 Neue Sulfooxybenzamide New Sulfooxybenzamide |
| 05/02/2002 | DE10049549A1 Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40 |
| 05/02/2002 | DE10049483A1 Substituierte 1-Aminobutan-3-ol-Derivate Substituted 1-aminobutan-3-ol derivatives |
| 05/02/2002 | DE10049481A1 Substituierte C-Cyclohexylmethylamin-Derivate C-substituted derivatives cyclohexylmethylamine |
| 05/02/2002 | CA2689012A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2427079A1 Total glycosides of dangshen and their use as an aid for memory acquisition, retention and/or retrieval |
| 05/02/2002 | CA2427070A1 Preferred segments of neural thread protein and methods of using the same |
| 05/02/2002 | CA2427024A1 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | CA2427005A1 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | CA2426902A1 Methods of improving central nervous system functioning |
| 05/02/2002 | CA2426706A1 Benzoxazinone derivatives, their preparation and use |
| 05/02/2002 | CA2426564A1 Pyranoside derivatives |
| 05/02/2002 | CA2426007A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/02/2002 | CA2425908A1 Mammalian metabolites of a tachykinin receptor antagonist |
| 05/02/2002 | CA2425288A1 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | CA2425283A1 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2425280A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2424475A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2420164A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/01/2002 | CN1347414A Triazole compounds with dopamine-D3-receptor affinity |
| 05/01/2002 | CN1347408A Use of maduraphthalazine derivs. as inhibitors of pro-inflammatory cytokins |
| 05/01/2002 | CN1347406A Carbamic acid derivs. and their use as metabotropic glutamate receptor ligands |
| 05/01/2002 | CN1347325A Novel amide derivs. as growth hormone secretagogues |
| 05/01/2002 | CN1347317A Remedies |
| 05/01/2002 | CN1347316A Composition for preventing or treating dementia comprising hydroxycinnamic acid deriv. or extract of plant of genus angelicae contg. same |
| 05/01/2002 | CN1347315A Method for producing water-insoluble amorphous or partially amorphous controlled release matrix |
| 05/01/2002 | CN1347313A High potency dihydroergotamine compositions |
| 05/01/2002 | CN1346831A Purified polypeptide with bioactivity and medicine prepared from it for promoting growth and development of animal's nerve cells and suppressing their apotosis |
| 05/01/2002 | CN1346676A Medicine for treating nerve injury |
| 05/01/2002 | CN1346675A Chinese patent medicine for treating paraplegia |
| 05/01/2002 | CN1346648A Diemailing injection and its preparing process |
| 05/01/2002 | CN1083843C 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano [2,3-e] indol-8-ones and derivs., and pharmaceutical compositions thereof |
| 05/01/2002 | CN1083842C [1,2,4] triazolo [4,3-a] quinoxalinone derivs., their preparation and use |
| 05/01/2002 | CN1083840C 8-azabicyclo [3.2.1] oct-2-ene derivs., their preparation and use |
| 05/01/2002 | CN1083830C Substd. benzamidines, their production and their use as medicaments |
| 04/30/2002 | US6380396 Chemical intermediates for antiinflammatory agents |
| 04/30/2002 | US6380258 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 04/30/2002 | US6380244 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 04/30/2002 | US6380242 For diagnosis and therapy of central nervous system conditions |
| 04/30/2002 | US6380238 Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands |
| 04/30/2002 | US6380230 For therapy of dyskinesia, obesity, irritable bowel syndrome, diseases whose treatment requires stimulation of the cholecystokinin cck-a receptors |
| 04/30/2002 | US6380226 For therapy of migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with a vascular disorder, depression, anxiety, an eating disorder, obesity, drug abuse, hypertension and emesis |
| 04/30/2002 | US6380224 For therapy of eating disorders, obesity, bulimia nervosa, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression and anxiety |
| 04/30/2002 | US6380223 For therapy of diseases, such as obesity, diabetes, inflammation |
| 04/30/2002 | US6380220 Therapy of neurodegenerative diseases and neuronal injuries which are casued by ischemia, trauma or massive hemorrhages |
| 04/30/2002 | US6380218 For therapy of respiratory, allergic, and inflammatory disorders comprising asthma, chronic obstructive pulmonary disease, acute respiratory disease syndrome, pulmonary hypersensitivity, and allergic rhinitis in a mammal |
| 04/30/2002 | US6380216 Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
| 04/30/2002 | US6380213 Compounds useful as neuro-protective agents |
| 04/30/2002 | US6380211 For treating diabetes |
| 04/30/2002 | US6380209 Highly selective agonists, antagonists or inverse agonists for gaba brain receptors or prodrugs, useful in the diagnosis and treatment of anxiety, down syndrome, sleep, cognitive and seizure disorders |
| 04/30/2002 | US6380208 Administering nicergoline, optionally in combination with a pharmaceutically acceptable carrier for therapy of pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway |
| 04/30/2002 | US6380205 2-cyclohexyl quinazoline NMDA/NR2B antagonists |
| 04/30/2002 | US6380204 Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist activity |
| 04/30/2002 | US6380199 Treatment of attention deficit hyperactivity disorder |
| 04/30/2002 | US6380186 Psychotherapeutic agents |